Abdul Majid, Mahnoor Rehman Khan




Trans-arterial chemoembolization (TACE) is the first line treatment in limited unresectable multinodular lesions, with no vascular invasion, no extrahepatic spread and with well- preserved liver functions. Post TACE reduction in tumour burden can be assessed by modified RECIST (mRECIST) criteria on follow up Triphasic CT in which tumour enhancement is evaluated within 3 months after TACE.


 The aim of this study was to evaluate the efficacy of trans-arterial chemo embolization therapy in cirrhotic patients with HCC on follow up quadriphasic computed tomography.

Material and method

This study is a retrospective study that was conducted from March 2016 to January 2019 at Radiology unit Kuwait Teaching Hospital. 181 consecutive cirrhotic patients with HCC, treated with trans-arterial chemoembolization and evaluated with follow-up quadriphasic CT at a Radiology unit of Kuwait Teaching Hospital. All patients had least one image examination (quadriphasic contrast-enhanced CT) after treatment and were included into the study.


Between March 2016 and January 2019, 181 consecutive patients diagnosed with hepatocellular carcinoma presented for TACE. Response assessment in the largest lesion on the basis of mRECIST criteria revealed complete response(CR) in 78, partial response(PR) in 96 , stable disease(SD) in 1 and progressive disease(PD) in 6 patients.


High quality screening, proper management and provision of therapy improves survival from HCC. Early and accurate assessment of tumour response to therapy is mandatory.

Key words

Hepatocellular carcinoma, TACE, quadriphasic CT, mRECIST criteria.

Full Text:




Raoul JL, Forner A, Bolondi L, Cheing TT, Kloeckner R. Updated use of TACE for hepatocellular carcinoma treatment. How and when to use it based on clinical evidence. Cancer Treatment Reviews 2019; 72:28-36.

Wong MC, Jiang JY, Goggin WB, Liang M, Fang Y, Fung FD et al. International incidence and mortality trends of liver cancer: a global profile. Sci Rep 2017 ;7 e45846.

Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet 2018; 391:1301-14.

EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018;69:1.

Kan Z, Wright K, Walace S. Ethiodized oil emulsions in hepatic microcirculation: in vivo microscopy in animal bodies. Acad Radiol 1997;4: 275-82.

Kan Z, Wallace S. Sinusoidal embolization: impact of iodized oil on hepatic microcirculation . J. Vasc Interv Radiol 1994; 5:881-6.

Shim JH, Lee HC, Kim SO, Shim YM, Kin KM, Lim YS et al. Which response criteria best help predict survival of patients with hepatocellular carcinoma following chemoembolization? A validation study of old and new models. Radiology 2012; 262:708-18

Liu L, Wang W, Chen H, Zhao Y, Bai W, Yin Z et al. EASL- and m RECIST- evaluated responses to combination therapy of sorafenib with transarterial chemoembolization predict survival in patients with hepatocellular carcinoma. Clin Cancer Res 2014; 20: 1623-31.

Marin D,Cappabianca S, Serra N, Sicca A, Lassandro F, Porta ML et al. CT appearance of hepatocellular carcinoma after locoregional treatments:A comprehensive review. Gastroenterology Research and Practice 2015;2015:1-10

Jiang T, Zhu AX, Sahani DV. Established and novel imaging biomarkers for assessing response to therapy in hepatocellular carcinoma. J Hepatol. 2013 Jan;58(1):169-177.

Lencioni R, Llovet JM. Modifed RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 2010;30:52–60.

Benzoin E, Malaro R, Cedolini C, Favero A, Cojutti A, Lorenzin D et al. Liver resection for HCC: analysis of causes and risk factors linked to postoperative complications. Hepatogastroenterology 2007;54:186-189.

Llovet JM, Bruix J. Systemic review of randomized trials for unresectable hepatocellular carcinoma . Chemoembolization improves survival. Hepatologyb2003;37:429-442.

Luo J, Guo RP, Lai EC, Zhang YJ, Lau WY, Chen MS et al. Transarterial chemoembolization for unresectable hepatocellular carcinoma with prospective comparative study. Ann Surg Oncol 2011;18:413-20.

Liem MS, Poon RT, Lo CM, Tso Wk, Fan ST. Outcome of transarterial chemoembolization in patients with inoperable hepatocellular carcinoma eligible for radiofrequency ablation. World J. Gastroenterol 2005;11:4465-4471.

Miraglia R, Pietrosi G, Maruzzelli L, Petridis I, Caruso S, Marrone G et al. Efficacy of transcatheter embolization (TAE/ TACE) for treatment of single hepatocellular carcinoma. World J. Gastroenterol 2007;13(21):2952-2955.

Matsui O, Kadoya M, Yoshikawa J, Gabata T, Arai K, Demachi H et al. Small hepatocellular carcinoma treatment with subsegmental transcatheter arterial embolization. Radiology 1933;188:79-83.


  • There are currently no refbacks.

© Copyright PJR 2008-